Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: July 22, 2017
What is the competitive landscape for ENDO PHARMS INC, and what generic alternatives to ENDO PHARMS INC drugs are available?
ENDO PHARMS INC has five approved drugs.| Patents: | 14 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endo Pharms Inc | NASCOBAL | cyanocobalamin | SPRAY, METERED;NASAL | 021642-001 | Jan 31, 2005 | RX | Yes | Yes | 7,879,349 | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | AB | RX | Yes | Yes | 9,107,827 | ► Subscribe | ► Subscribe | |||||||||||||||||
Endo Pharms Inc | AVEED | testosterone undecanoate | INJECTABLE;INTRAMUSCULAR | 022219-001 | Mar 5, 2014 | RX | Yes | Yes | ► Subscribe | ► Subscribe | |||||||||||||||||||
Endo Pharms Inc | AVEED | testosterone undecanoate | INJECTABLE;INTRAMUSCULAR | 022219-001 | Mar 5, 2014 | RX | Yes | Yes | 8,338,395 | ► Subscribe | ► Subscribe | ||||||||||||||||||
Endo Pharms Inc | COLY-MYCIN S | colistin sulfate; hydrocortisone acetate; neomycin sulfate; thonzonium bromide | SUSPENSION/DROPS;OTIC | 050356-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ► Subscribe | ► Subscribe | |||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | 5,145,684 | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
cyanocobalamin | Nasal Spray | 500 mcg/spray | NASCOBAL | 4/28/2017 |
testosterone undecanoate | Injection | 250 mg/mL | AVEED | 6/11/2014 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,521,068 | Dry powder aerosols of nanoparticulate drugs | ► Subscribe | |||||||||||||||||||||||||||
| 8,293,277 | Controlled-release nanoparticulate compositions | ► Subscribe | |||||||||||||||||||||||||||
| 6,969,529 | Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers | ► Subscribe | |||||||||||||||||||||||||||
| 8,652,464 | Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer | ► Subscribe | |||||||||||||||||||||||||||
| 7,198,795 | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Slovenia | 1457208 | ► Subscribe | |||||||||||||||||||||||||||
| World Intellectual Property Organization (WIPO) | 2009120919 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 2263652 | ► Subscribe | |||||||||||||||||||||||||||
| South Korea | 101216853 | ► Subscribe | |||||||||||||||||||||||||||
| Spain | 2271772 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0003 | France | ► Subscribe | PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920 | ||||||||||||||||||||||||||
| 00071 | Netherlands | ► Subscribe | PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920 | ||||||||||||||||||||||||||
| 02/028 | Ireland | ► Subscribe | PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013 | ||||||||||||||||||||||||||
| C/GB02/027 | United Kingdom | ► Subscribe | PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,067 other biopharmaceutical professionals who get our Drug Patent Expiration Alerts:
